바이오스펙테이터

바이오스펙테이터 Jongwon Jang 기자

Samsung Biologics, a biopharmaceutical unit of Korea’s Samsung Group, reports its biopharmaceutical manufacturing deals reached $154 million in the first half of 2017.

According to the Financial Supervisory Service’s DART (Data Analysis, Retrieval and Transfer System), Samsung Biologics reported a total of overseas orders worth $3.273 billion from 2005 to the end of June 2017.

The six-month figure of 2017 represents an increase of $154 million or 4.9%, compared to the end of 2016 ($3.119 billion), reflecting significant growth by $371 million (approximately 420 billion won) from October 2016, when reported by Samsung Biologics for listing in the Korean stock market.

In its first-half regulatory filing, Samsung Biologics reported that it secured biopharmaceutical manufacturing contracts with two European-based pharmaceutical companies ($41.654 million in May and 15.73 billion in July), and India’s Sun Pharmaceutical Industries ($55 million in July).

Under the long-term deal, Sun Pharmaceutical Industries appointed Samsung Biologics to manufacture tildrakizumab, an inhibitor for treatment of moderate to severe psoriasis. Sun Pharmaceutical Industries is India’s top pharmaceutical company and the world’s fourth ranked specialty generic producer.

Samsung Biologics already shipped its contract volume worth $493 million, with remaining volume of $2.78 billion to be delivered through 2028.

“The total contract volume is computed from our product sales based on ‘take or pay’ rule,” Samsung Biologics reported. “Beyond the ‘take or pay’ agreement, it is expected that more increased orders from buyers may be available and if this is the case, our actual sales may further increase,” Samsung Biologics noted.